Isomorphic Labs

Health

Lilly is putting $6.5 billion into concrete and up to $1 billion into AI drug discovery

Investors moved this week to mark Lilly's AI-discovery partner Isomorphic Labs at up to $50 billion, a company that has never dosed a patient. Lilly's own ledger, $6.5 billion of concrete against at most $1 billion of AI, says which bet it trusts.

October 9, 2026 · 3 min read

Health

Isomorphic Labs' reported $40 billion raise prices Biohub's $1.8 billion cell-data pact

Biohub's virtual-cell commons counts $300 million of new corporate money inside a $1.8 billion headline that leans on federal funds and already-bought assets, and gives commercial partners a one-year exclusive window on the data they fund. That is the substrate under Isomorphic Labs' reported $40 billion ask.

October 9, 2026 · 3 min read

Health

Isomorphic says its AI is proven; $2.7 billion rides on a 31 December deadline

Isomorphic Labs' president says its AI hypothesis "has been proven." The ledger shows $2.7 billion raised, $82.5 million banked from partners, no drug named and no trial started, with the company's own year-end deadline 13 weeks away.

October 2, 2026 · 3 min read

Secondary market

Latest on Isomorphic Labs

Novo Nordisk and Eli Lilly pay Anthropic and other AI labs for drug tools; no AI-designed drug is approved

Lilly is putting $6.5 billion into concrete and up to $1 billion into AI drug discovery

Isomorphic Labs' reported $40 billion raise prices Biohub's $1.8 billion cell-data pact

Isomorphic says its AI is proven; $2.7 billion rides on a 31 December deadline

Also mentioned in

Google prices Gemini 4 Argon at $2 per million tokens, a fifth of OpenAI and Anthropic's $10 flagships